Merck reported that adding Welireg (belzutifan) to an existing Keytruda regimen did not produce a significant improvement in newly diagnosed patients with advanced kidney cancer. The negative result marks a setback for the combination strategy and reduces expectations that Welireg could secure first-line expansion in this setting. While the company did not indicate new safety concerns in the provided update, the trial outcome removes a potential blockbuster pathway. The readout comes amid heightened competition in advanced RCC and in the broader landscape of combination immunotherapy plus targeted agents. For biotech stakeholders, the takeaway is that even mechanistically rational combinations face high bar endpoints in first-line settings, where historical control efficacy and patient selection can heavily influence outcomes. The result also may influence how investors and developers weigh next combination experiments with hypoxia-pathway drugs.